Business Context and Reporting Period
This Form 8-K filing by Calidi Biotherapeutics, Inc. (CLDI) covers events occurring between April 17, 2025, and April 23, 2025. The report details a significant leadership transition involving the resignation of the Chief Executive Officer (CEO) and Chairman of the Board, the appointment of a new CEO and director, and the election of a new Chairman.
Key Financial Metrics and Compensation Arrangements
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, or debt levels. However, it discloses specific financial obligations related to executive compensation and severance:
- Outgoing CEO Severance: Allan Camaisa is entitled to $500,000 in separation pay (paid over 12 months), 12 months of COBRA premiums, and a transition consulting fee of $10,000 per month.
- Incentive Payments: Mr. Camaisa may receive incentive payments based on revenues, capital, or monies received by the Company on or before December 31, 2026.
- New CEO Compensation: Eric Poma, Ph.D., will receive an annual base salary of $535,000 and an annual bonus target of up to 50% of his base salary.
- Equity Grant: Dr. Poma received an option to purchase 726,412 shares of common stock, vesting 25% on the first anniversary and the remainder ratably over three years.
Material Changes Versus Prior Period
The primary material change is the restructuring of the Company's executive leadership and Board composition:
- CEO Resignation: Allan Camaisa resigned as CEO and Chairman effective April 21, 2025. He will retain the title of "CEO Emeritus" and continue as a Class III director.
- New CEO Appointment: Eric Poma, Ph.D., was appointed CEO effective April 22, 2025.
- Board Expansion: The Board size was increased from five to six members to accommodate Dr. Poma's appointment as a Class I director.
- New Chairman: James Schoeneck was appointed Chairman of the Board effective April 22, 2025.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, operational outlook, or specific risk factors beyond the standard disclosures regarding the transition. Key points include:
- Transition Stability: The resignation of Mr. Camaisa is explicitly stated as not being the result of any disagreement with the Company or its Board.
- Severance Contingencies: Severance benefits for both the outgoing and incoming CEOs are contingent upon the execution of a general release of claims.
- Change in Control Provisions: Dr. Poma's employment agreement includes enhanced severance (24 months of salary) if terminated without Cause or for Good Reason within 12 months of a Change in Control.
Investor Verification Checklist
- Verify the finalization of the General Release of Claims and Transition Agreement with Allan Camaisa after the seven-business-day revocation period.
- Review the full text of Exhibit 10.1 (Release Agreement) and Exhibit 10.2 (Employment Agreement) for detailed terms regarding vesting schedules and termination triggers.
- Monitor the Company's cash burn rate given the immediate cash obligations for Mr. Camaisa's separation pay and the new CEO's salary.
- Confirm the impact of the leadership change on the Company's clinical development pipeline and strategic direction in subsequent press releases or 10-Q filings.